NCT03122197 2026-04-16
Study of Letrozole in Recurrent Gliomas
University of Cincinnati
Phase EARLY_PHASE1 Recruiting
Clinical Trials
16 trialsNCT06179303 2026-04-16
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT02095184 2026-04-15
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
University of Maryland, Baltimore
Phase NA Terminated
NCT04852887 2026-04-15
DEBRA
NRG Oncology
Phase 3 Recruiting
NCT01127295 2026-04-14
PHACS
Institut Claudius Regaud
Phase 4 Completed
NCT01553903 2026-04-14
OXYTAM
Institut Claudius Regaud
Phase 4 Completed
NCT01612871 2026-04-14
MIRHO
Institut Claudius Regaud
Phase 4 Completed
NCT03625531 2026-04-14
A Trial of Personalized Acupuncture, Fixed Acupuncture, Letrozole and Placebo on Live Birth in Women With PCOS
The First Affiliated Hospital of Guangzhou Medical University
Phase 3 Completed
NCT04895761 2026-04-13
Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
Providence Health & Services
Phase 1 Active not recruiting
NCT04886531 2026-04-08
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT05467891 2026-04-08
RaPhLRR
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT05286437 2026-04-06
LaPemERLA
National Cancer Centre, Singapore
Phase 2 Recruiting
NCT04569747 2026-04-02
ADEPT
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT07492394 2026-04-02
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT04486352 2026-04-01
EndoMAP
Alliance Foundation Trials, LLC.
Phase 1/2 Recruiting
NCT04095364 2026-03-24
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NRG Oncology
Phase 3 Active not recruiting